A new complete tool about µsmin (Microsmin) Plus, the bioenhanced diosmin for leg comfort and vein health, is now available with the results of the latest clinical trial
The purpose of this white paper is to offer an overview of CVI including its prevalence, causes, common symptoms, risk factors and limitations of available treatments. In this context, μsmin Plus represents an innovative and valid therapeutic tool that can offer supplement brand owners a new way to tackle the leg health market dominated by micronised diosmin preparations.
Healthy leg veins are essential for the normal return of blood from the legs to the heart. If leg veins fail to act in a normal manner and become compromised, there is a blockage of normal blood flow, and blood can pool in the legs. This can lead to leg pain, swelling, itchiness, restless leg syndrome, a burning sensation, and heaviness and can significantly affect the quality of life. Notably, the global burden of venous problems including varicose veins and chronic venous insufficiency (CVI) is increasing worldwide.
The initial management of CVI relies on conservative strategies to reduce symptoms, avoid complications and prevent disease progression. Several natural compounds that function as phlebotonics have been found helpful in the management of vein issues. Phlebotonics are compounds that improve circulatory function and vein health, such as diosmin, horse chestnut seed extract, grape seed extract, pycnogenol, and Centella asiatica. Among the various nutrients studied, diosmin has been demonstrated the greatest clinical benefits with leg venous problems. Notably, clinical practice guidelines issued by the Society for Vascular Surgery and the American Venous Forum recommended the use of diosmin in conjunction with compression therapy to treat pain, swelling, and ulcers due to CVI.
Developed by Giellepi Ingredients’ business unit, μsmin (Microsmin) Plus is the next generation diosmin (>80% diosmin and 90% total flavonoids) that overcomes common absorption issues related to diosmin. The results from a new clinical study in subjects with mild to moderate symptoms of CVI confirm the efficacy of μsmin Plus in improving symptoms and quality of life. To download a free copy of the paper click here.
Thanks to its research activity oriented to the knowledge of the functional ingredients and thanks to its consolidated partnerships with important international manufacturing companies, Giellepi Ingredients offers its customers a high level of expertise for the launch of formulations with unique features.
Innovation, research and science are the key elements that distinguish Giellepi in the health products market.
Giellepi will attend the Vitafoods Europe in Geneva from 5-7 October, meet the team at booth #H99 and get a copy of the white paper.